Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,909 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Sudhan DR, et al. Among authors: ye d. Cancer Cell. 2020 Feb 10;37(2):183-199.e5. doi: 10.1016/j.ccell.2019.12.013. Epub 2020 Jan 23. Cancer Cell. 2020. PMID: 31978326 Free PMC article.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Sudhan DR, Guerrero-Zotano A, Won H, Ericsson PG, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Brewer MR, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Sudhan DR, et al. Among authors: ye d. Cancer Cell. 2020 Feb 10;37(2):258-259. doi: 10.1016/j.ccell.2020.01.010. Cancer Cell. 2020. PMID: 32049049 Free PMC article. No abstract available.
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Hanker AB, et al. Among authors: ye d. Cancer Cell. 2021 Aug 9;39(8):1099-1114.e8. doi: 10.1016/j.ccell.2021.06.001. Epub 2021 Jun 24. Cancer Cell. 2021. PMID: 34171264 Free PMC article.
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. Lee KM, et al. Among authors: ye d. Cancer Immunol Res. 2022 Jul 1;10(7):829-843. doi: 10.1158/2326-6066.CIR-21-0826. Cancer Immunol Res. 2022. PMID: 35561311 Free PMC article.
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis MJ, Chang EC. Kim BJ, et al. Among authors: ye d. Cancer Res Commun. 2023 Jul 26;3(7):1366-1377. doi: 10.1158/2767-9764.CRC-23-0044. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37501682 Free PMC article.
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: ye d. Res Sq [Preprint]. 2023 Jul 10:rs.3.rs-2966905. doi: 10.21203/rs.3.rs-2966905/v1. Res Sq. 2023. Update in: Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2 PMID: 37502925 Free PMC article. Updated. Preprint.
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: ye d. Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. Nat Commun. 2024. PMID: 38480701 Free PMC article.
3,909 results